Albemarle vs Avient
ALB and AVNT side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALB and AVNT compare
Albemarle is the larger company, worth 2.7 times as much as Avient ($11.0B against $4.1B).
On earnings, Albemarle is cheaper: it trades at 22.6× trailing earnings, against 22.9× for Avient.
Albemarle grew revenue faster over the last twelve months (24.4% versus 5.2% for Avient).
Albemarle keeps more of each dollar of sales as profit, with a net margin of 11.1% compared with 5.3% at Avient.
Both pay dividends: Albemarle yields 1.7% and Avient 2.5%.
Albemarle scores higher on the StockData Score (19 against 13 for Avient), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALB | AVNT |
|---|---|---|
| Size and price | ||
| Market cap | $11.0B | $4.1B |
| Share price | $93.53 | $44.66 |
| Change, 1 year | −15.2% | 51.6% |
| Change, 5 years | −66.8% | −25.6% |
| Beta (5Y) | 1.64 | 1.33 |
| Employees | 7,800 | 9,000 |
| StockData Score | ||
| Total score | 19 (better) | 13 |
| Valuation score | 5 (better) | 3 |
| Growth score | 3 (better) | 2 |
| Performance score | 3 (better) | 2 |
| Health score | 4 (better) | 2 |
| Dividend score | 4 | 4 |
| Valuation | ||
| P/E | 22.6× (better) | 22.9× |
| P/S | 1.8× | 1.2× (better) |
| P/B | 1.0× (better) | 1.7× |
| EV/EBITDA | 9.0× (better) | 10.5× |
| P/FCF | 7.6× (better) | 17.1× |
| FCF yield | 13.1% (better) | 5.8% |
| Fair value | $150.41 | $54.00 |
| Margin of safety | 37.8% (better) | 17.3% |
| Growth | ||
| Revenue growth (TTM) | 24.4% (better) | 5.2% |
| Revenue growth, 5Y average | 10.4% (better) | 8.0% |
| Net income growth (TTM) | – | 59.0% |
| EPS growth (TTM) | – | 57.3% |
| EPS growth, 5Y average | – | −9.3% |
| Profitability | ||
| Gross margin | 25.8% | 31.7% (better) |
| Operating margin | 10.0% (better) | 9.7% |
| Net margin | 11.1% (better) | 5.3% |
| FCF margin | 23.5% (better) | 7.0% |
| Return on equity | 6.6% | 7.5% (better) |
| Return on invested capital | 2.8% | 6.4% (better) |
| Financial health | ||
| Debt / equity | 0.18 (better) | 0.74 |
| Net debt / EBITDA | 0.03 (better) | 2.65 |
| Current ratio | 2.34 (better) | 1.71 |
| Altman Z-score | 2.42 (better) | 1.59 |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Dividend yield | 1.7% | 2.5% (better) |
| Payout ratio | 28.0% | 55.7% |
| Years of dividend growth | 16 (better) | 15 |
| Dividend growth, 5Y average | 1.0% | 5.8% (better) |
| Shareholder yield | 1.7% | 2.5% (better) |
| Ownership | ||
| Held by institutions | 98.3% | 105% |
| Held by insiders | 0.35% | 0.83% |
| Insider net buying, 12 months | −$7.4M | – |
| Short interest, % of float | 10.5% | 4.7% |
Go deeper
- ALB stock overview
- ALB income statement
- ALB valuation and score
- AVNT stock overview
- AVNT income statement
- AVNT valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.